RNXT
RenovoRx Inc

3,229
Mkt Cap
$43.98M
Volume
376,105.00
52W High
$1.69
52W Low
$0.75
PE Ratio
-3.20
RNXT Fundamentals
Price
$1.19
Prev Close
$1.20
Open
$1.20
50D MA
$1.15
Beta
0.82
Avg. Volume
824,116.00
EPS (Annual)
-$0.3958
P/B
4.13
Rev/Employee
$4,300.00
Loading...
Loading...
News
all
press releases
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwrights 27th Annual Global Investment Conference in New York City, September 8-10, 2025
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared...
Business Wire·2mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +22.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
Zacks·5mo ago
News Placeholder
RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery...
Business Wire·8mo ago
News Placeholder
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device...
Business Wire·8mo ago
News Placeholder
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared delivery...
Business Wire·8mo ago
News Placeholder
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared delivery platform...
Business Wire·9mo ago
News Placeholder
RenovoRx Announces Proposed Public Offering
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared delivery platform...
Business Wire·9mo ago
News Placeholder
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared delivery platform...
Business Wire·9mo ago

Latest RNXT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.